Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Angiotensin II type 1 (AT(1)) receptor blockade in hypertensive women: Benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide
Autore:
Malmqvist, K; Kahan, T; Dahl, M;
Indirizzi:
Danderyd Hosp, Karolinska Inst, Div Internal Med, S-18288 Danderyd, SwedenDanderyd Hosp Danderyd Sweden S-18288 rnal Med, S-18288 Danderyd, Sweden Hassle Lakemedel AB, Molndal, Sweden Hassle Lakemedel AB Molndal SwedenHassle Lakemedel AB, Molndal, Sweden
Titolo Testata:
AMERICAN JOURNAL OF HYPERTENSION
fascicolo: 5, volume: 13, anno: 2000,
parte:, 1
pagine: 504 - 511
SICI:
0895-7061(200005)13:5<504:AIT1(R>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
QUALITY-OF-LIFE; BLOOD-PRESSURE; SYSTOLIC HYPERTENSION; EFFICACY; TOLERABILITY; POPULATION; ANTAGONIST; VALSARTAN; DISEASE; MEN;
Keywords:
hypertension; women; AT(1)-receptor blocker; candesartan cilexetil; enalapril; hydrochlorothiazide; quality of life;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Malmqvist, K Danderyd Hosp, Karolinska Inst, Div Internal Med, S-18288 Danderyd, Sweden Danderyd Hosp Danderyd Sweden S-18288 8288 Danderyd, Sweden
Citazione:
K. Malmqvist et al., "Angiotensin II type 1 (AT(1)) receptor blockade in hypertensive women: Benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide", AM J HYPERT, 13(5), 2000, pp. 504-511

Abstract

The aim of this large, randomized, double-blind, parallel-group study in hypertensive women was to compare the antihypertensive efficacy and effects on subjective symptoms and quality of life of the new angiotensin II type 1(AT(1)) receptor blocker candesartan cilexetil, the angiotensin-convertingenzyme inhibitor enalapril, and the diuretic hydrochlorothiazide (HCTZ). Women, aged 40 to 69 years, with a seated diastolic blood pressure (DBP) of 95 to 115 mm Hg, were randomized to candesartan cilexetil, 8 to 16 mg (n = 140), enalapril, 10 to 20 mg (n = 146), or HCTZ, 12.5 to 25 mg (n = 143), for 12 weeks; the higher doses were used if DBP was greater than 90 mm Hg after 6 weeks. Candesartan cilexetil lowered seated blood pressure by 17/11 and 19/11 mm Hg after 6 and 12 weeks of treatment, respectively. This reduction was greater (P < .01) than with enalapril (12/8 and 13/9 mm Hg) or HCTZ(12/7 and 13/8 mm Hg). The proportions of patients with controlled DBP (< 90 mm Hg) after 12 weeks of treatment with candesartan cilexetil, enalapril, or HCTZ were 60%, 51% and 43%, respectively. Patients experienced less dry cough (P < 0.001) with candesartan cilexetil or HCTZ than with enalapril. No treatment differences were found in the incidence of dizziness and quality of life was well maintained in all groups. Compared with candesartan cilexetil and enalapril, HCTZ increased uric acid and decreased serum potassium (P < .001). In conclusion, candesartan cilexetil reduced blood pressure more effectively and was better tolerated than enalapril or HCTZ in women with mild to moderate hypertension. (C) 2000 American Journal of Hypertension, Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 15:21:02